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Contemporary attitudes toward cannabis use in the United States have shifted from War on Drugs-
era prohibition toward decriminalization over the past two decades.  As states that do not seek to 
decriminalize marijuana nonetheless enact legislation legalizing CBD, policy tensions arise. In 
2019, Texas joined the ranks of states that legalized hemp and hemp-derived products with the 
passage of House Bill 1325.  In light of this legislation, this Article discusses the implications of 
legalized cannabidiol (CBD) on employment drug policies in Texas.  The benefits of CBD 
legalization must be weighed against the practical implications to effectively balance policies that 
aim to protect employees and employers with potentially divergent interests.  This Article examines 
the various sources of employment protection in Texas and advocates for an amendment to H.B 
1325 that raises the threshold of delta-9 tetrahydrocannabidiol (THC) content permitted in hemp, 
an adoption of administrative rules modeled after those established by the Utah Department of 
Agriculture and Food, and an amendment to the Texas Labor Code.  This approach places the 
burden on CBD sellers to verify that their products are consistent with claimed CBD content, 
ensures that the products produce no psychoactive effects, allows room for error in the event of 
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Seventy-two-year-old Lena Bartula takes cannabidiol (CBD) to treat pain caused by her sciatica.1  
On September 16, 2018, she passed through Texas during her trip from Mexico to Portland, Oregon 
to visit her granddaughter.2  At DFW Airport, however, police arrested her when a bag check at 
the customs checkpoint yielded the discovery of her CBD oil.3  Testing instruments could not 
differentiate between CBD and tetrahydrocannabidiol (THC), and she was charged with 
possession of a controlled substance.4  Bartula was booked, fingerprinted, given a tuberculosis 
vaccine shot without her consent, and jailed for two days at the Tarrant County Jail.5  Although 
she was released, Bartula’s case was not dismissed until two months later, when a grand jury 
declined to indict her.6 
 
As CBD use skyrockets,7 consumers like Bartula must contend with possible criminal 
implications.  However, Bartula’s case highlights another aspect of life that may be affected: 
employment.  While CBD is now legal at both the federal and state levels, consumers face 
occupational ramifications if they test positive for THC, even if they have never used marijuana.8  
Due to CBD’s relatively new presence in the market, the Federal Drug Administration (FDA) has 
yet to develop standards and regulations governing the content of CBD products.9  The Texas 
government lacks the requisite testing equipment to ascertain whether CBD products satisfy the 
statutorily required THC threshold.10  Remedies under the Americans with Disabilities Act (ADA) 
and Texas Labor Code are unavailable due to the alleged use of illegal drugs.11  The recent 
legalization of CBD, therefore, allowed consumers access to a whole new market, but failed to 
implement policies to ensure their safety.  Instead, Texas consumers face onerous consequences 
without ever breaking the law. 
 
1 Carlos Miller, Stop Arresting Grandmothers for CBD, MIAMI NEW TIMES (May 28, 2019), 
https://www.miaminewtimes.com/marijuana/stop-cbd-cannabidol-marijuana-arrests-of-grandmothers-hester-
burkhalter-and-lena-bartula-11181105.  
2 Id.; Mitch Mitchell, Still Illegal: Texas Law on CBD Oil Lands Grandmother in Jail After DFW Airport Search, 
FORT WORTH STAR-TELEGRAM (May 22, 2019), https://www.star-telegram.com/news/local/article230704704.html.  
3 Mitchell, supra note 2. 
4 Miller, supra note 1. 
5 Mitchell, supra note 2. 
6 Id. 
7 Matej Mikulic, Total U.S. Cannabidiol (CBD) Consumer Sales from 2014 to 2022, STATISTA (Sept. 2018), 
https://www.statista.com/statistics/760498/total-us-cbd-sales/ (last updated Sept. 23, 2020). 
8 See Horn v. Medical Marijuana, Inc., 383 F. Supp. 3d 114, 121–22 (W.D.N.Y. 2019). 
9 See generally Press Release, U.S. Food & Drug Admin., FDA Approves First Drug Comprised of an Active 
Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy, (June 25, 2018), 
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-
derived-marijuana-treat-rare-severe-forms. 
10 See Nicholas Bogel-Burroughs, Texas Legalized Hemp, Not Marijuana, Governor Insists as Prosecutors Drop Pot 
Charges, N.Y. TIMES (July 19, 2019), https://www.nytimes.com/2019/07/19/us/texas-hemp-marijuana-
legalization.html. 
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The goal of this Article is to analyze the scientific differences between marijuana and hemp, 
examine the formation of the legal definition of the substances, apply the existing employment 
protection structures to the recent legislation, and ultimately suggest a change in policy for state 
governments that have not legalized marijuana to implement in the future.  Part II of this Article 
will clarify the differences between marijuana, hemp, and CBD and will provide context for 
lawmakers’ decision to legalize hemp and CBD.  Part III will provide a historical background of 
the cannabis decriminalization processes in the United States to highlight how many states are 
further ahead of the curve regarding cannabis regulation.  
 
Then, Part IV of this Article will examine the current difficulty differentiating between marijuana 
and hemp from the perspectives of law enforcement and employers.  Part V will analyze the 
interaction between cannabis use and employment discrimination protection and the effect of CBD 
legalization on the existing structure.  A brief discussion of the ADA and the Texas Labor Code is 
necessary to understand the effect of marijuana use on the ability to implicate the statutory 
protections.  This section will also assess the lack of regulation of CBD products, the FDA’s 
current regulatory position regarding the presence of CBD products in interstate commerce, and 
possible protections under federal and state employment discrimination laws for users of CBD 
who may test positive for THC.    
 
Lastly, Part VI will propose a three-pronged amendment to Texas House Bill 1325: an increase of 
the THC threshold, the enactment of administrative rules by the Texas Department of Health 
mandating third-party verification of CBD products and state-allocated funding for enforcement, 
and an exception to the Texas Labor Code protecting individuals who disprove allegations of 
illegal drug use.  The proposed amendment provides a balance of interests that benefits both the 
economic and individual well-being of Texas citizens following the passage of H.B. 1325.   
 
II. Definitions of Marijuana, Hemp, & CBD 
  
There is confusion regarding the difference between hemp and marijuana, and how CBD factors 
into the equation.12  However, understanding those differences is the key to forming a practical 
employment policy regarding the use of CBD.  
 
Marijuana and hemp are two members of the cannabis genus.13  This species of plant produces a 
variety of chemical compounds known as cannabinoids.14  While the plant produces many different 
cannabinoids, the two relevant to this discussion are delta-9 tetrahydrocannabidiol and 
cannabidiol.15  Delta-9 tetrahydrocannabidiol, more commonly known as THC, is the cannabinoid 
 
12 See generally Peter Grinspoon, Cannabidiol (CBD) – What We Know and What We Don’t, HARV. HEALTH 
PUBL’G: HARV. HEALTH BLOG (Aug. 24, 2018, 6:30 AM), https://www.health.harvard.edu/blog/cannabidiol-cbd-
what-we-know-and-what-we-dont-2018082414476.  
13 DAVID P. WEST, N. AM. INDUS. HEMP COUNCIL, HEMP & MARIJUANA: MYTHS & REALITIES 3 (1998).      
14 See id. at 7. 
15 See id. See generally Ernest Small, Evolution and Classification of Cannabis Sativa (Marijuana, Hemp) in 
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responsible for inducing the psychoactive effect, or the notorious “high.”16  The cannabis plant 
must contain at least one percent THC in order to produce the psychoactive effect.17  Cannabidiol, 
commonly referred to as CBD, is a non-intoxicating cannabinoid that has been shown to reduce 
the effects of THC.18  A substance containing a high amount of CBD will thus be incapable of 
producing the “high” that marijuana is known for.19  Instead, scientific studies indicate that CBD 
produces anti-inflammatory and neuroprotective effects.20 
 
Marijuana is depicted frequently in the media and is likely the most recognizable recreational drug 
to the public.21  There are various stages of cultivation and an abundance of concentrated 
products.22  The typical method of consumption involves combustion or vaporization of a cured 
flower end product that generally contains anywhere from 3.4%  to 20% THC, and cannabis oils 
can contain as much as eighty percent THC.23  Hemp itself, referred to as “industrial hemp,” is the 
cannabis plant that has been cultivated to contain low amounts of THC and high amounts of 
CBD.24  
 
Put simply, marijuana and hemp are cousins in the cannabis genus and contain varying amounts 
of CBD and THC, with hemp containing more CBD than THC.25  Congress has defined “hemp” 
as the cannabis sativa plant that contains less than 0.3% THC on a dry-weight basis.26  A plant 
that contains 0.31% THC on a dry-weight basis, therefore, is legally classified as a marijuana plant, 
regardless of the fact that it does not produce marijuana’s psychoactive effect.27  In other words, 
Congress imposed definitions on naturally occurring plant products—a decision that seems 
somewhat laughable in light of the current tensions with respect to the differences between the two 
plants.  Hemp may be used in a multitude of products, such as fertilizer, cosmetics, cooking oils, 
paints, and automotive fuel.28  Its pervasiveness in the market, therefore, sets consumers up to face 
the issue of testing due to the heightened risk of inadvertently ingesting THC.  
 
 
16 WEST, supra note 13, at 7–8. 
17 Small, supra note 15, at 242. 
18 WEST, supra note 13, at 7–8. 
19 See id at 8. 
20 Lawrence Leung, Cannabis and Its Derivatives: Review of Medical Use, 24. J. AM. BD. FAM. MED. 452, 458–59 
(July 2011). 
21 See Steve P. Calandrillo & Katelyn Fulton, “High” Standards: The Wave of Marijuana Legalization Sweeping 
America Ignores the Hidden Risks of Edibles, 80 OHIO ST. L.J. 201, 203 (2019). 
22 See Paul J. Larkin, Jr., Marijuana Edibles and “Gummy Bears”, 66 BUFF. L. REV. 313, 318 (Apr. 2018). 
23 See id. at 318, 338. 
24 See WEST, supra note 13, at 8. 
25 See id.; Grinspoon, supra note 12. 
26 7 U.S.C.A. § 1639o(1) (West 2018). 
27 See Nicole Gleichmann, Hemp vs. Marijuana: Is There a Difference?, ANALYTICAL CANNABIS (Sept. 2, 2019), 
https://www.analyticalcannabis.com/articles/hemp-vs-marijuana-is-there-a-difference-311880. 
28 See DAVID G. KRAENZEL ET AL., INDUSTRIAL HEMP AS AN ALTERNATIVE CROP IN NORTH DAKOTA 7 fig.2 (Agric. 
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The Texas Legislature has designated CBD products marketed for individual use as consumable 
hemp products.29  CBD products may be labeled as one of three types: full-spectrum CBD, broad-
spectrum CBD, or CBD isolate.30  In full-spectrum CBD, all of the naturally occurring compounds 
in the cannabis plant are present, including terpenes, flavonoids, and THC.31  Such extracts are 
required to contain less than 0.3% THC, but compliance is difficult to ascertain due to the lack of 
available testing.32  Full-spectrum CBD is widely available.33  The second type of product is broad-
spectrum CBD, which is essentially full-spectrum CBD without THC.34  This type of CBD extract 
is less available than full-spectrum CBD.35  The third type of CBD product is CBD isolate, or pure 
CBD.36  It does not contain THC or any other compounds and is generally derived from the hemp 
plant itself.37  CBD isolate is typically sold as an oil, tincture, edible slab, or crystalline powder.38  
CBD and marijuana both take a variety of similar forms, and uninformed consumers may be unable 
to distinguish between them in order to comply with the law. 
 
III. History of Cannabis Decriminalization 
 
Having established the substantive differences between marijuana, hemp, and CBD, this Article 
next describes the historical background of the cannabis decriminalization processes in the United 
States, beginning with marijuana.  Had the legislative bodies considered this history, they may 
have been able to foresee, and thus prevent, the issues that have arisen. 
 
It is important to note, however, the difference between the terms “decriminalization” and 
“legalization.”  Decriminalization refers to “policies that do not define possession for personal use 
or casual distribution as criminal offenses.”39  For example, marijuana is decriminalized in 
Mississippi because a first-time offense of possession of fewer than thirty grams of marijuana is 
punishable by a $250 fine.40  Legalization, on the other hand, “removes the criminal and monetary 
 
29 See H.R. 1325, 86th Leg., Reg. Sess. (Tex. 2019). 
30 Alan Carter & Carly Vandergriendt, Does CBD Show Up on a Drug Test?, HEALTHLINE (Apr. 24, 2019), 
https://www.healthline.com/health/does-cbd-show-up-on-a-drug-test.  
31 Id. Terpenes are naturally occurring compounds that provide cannabis with its distinct scent. Flavonoids are 
metabolites that affect UV filtration, pigmentation, and nitrogen fixation. Sean M. O’Connor & Erika Lietzan, The 
Surprising Reach of FDA Regulation of Cannabis, Even After Descheduling, 68 Am. U. L. Rev. 823, 848 (2019). 
32 Carter & Vandergriendt, supra note 30. 
33 Id. See also Jessica Timmons, Best-Full-Spectrum CBD Oils, HEALTHLINE (Oct. 27, 2020), 
https://www.healthline.com/health/best-full-spectrum-cbd-oil; 10 Best Full Spectrum CBD Oil, BEST CBD, 
https://www.bestcbdoils.org/best-full-spectrum-cbd-oil/ (last visited Nov. 11, 2020). As the most widely available 
form of CBD, full-spectrum CBD implicates a higher likelihood that consumers will inadvertently ingest more THC 






39 Rosalie Liccardo Pacula & Rosanna Smart, Medical Marijuana and Marijuana Legalization, 13 ANN. REV. 
CLINICAL PSYCHOL. 397, 400 (2017). 
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penalties for the possession, use, and supply of marijuana for recreational purposes.”41  For 
example, marijuana is legalized in fifteen states and the District of Columbia, wherein citizens 
may freely purchase and consume marijuana.42  In other words, legalization and decriminalization 




Congress significantly acted upon the issue of marijuana for the first time in 1937 when it passed 
the Marihuana Tax Act.43  While the Act did not declare the drug illegal, it implemented various 
requirements and taxes that paralyzed the marijuana industry.44  In 1970, Congress acted again by 
repealing the Marihuana Tax Act and replacing it with the Comprehensive Drug Prevention and 
Control Act, which effectively declared all cannabis illegal—regardless of whether it was 
marijuana or hemp.45  Title II of the Act, known as the Controlled Substances Act (CSA), contains 
five categories, or schedules, in which substances may be placed.46  Congress categorized 
substances based on possibility of abuse, accepted medical use in treatment, and degree of 
dependence.47  Upon its enactment, the CSA classified marijuana as a Schedule I drug.48  A drug 
or substance placed in Schedule I has a high possibility for abuse and lacks both any “currently 
accepted medical use in treatment in the United States” and “accepted safety for use under medical 
supervision.”49  This framework relies on legislative action; it lacks a self-updating mechanism to 
reschedule drugs, resulting in laws that lag behind accepted medical uses, particularly in light of 
severe restrictions on marijuana research.50  
 
In the same year that Congress enacted the CSA, President Richard Nixon announced a national 
“war on drugs.”51  In 1972, he appointed the National Commission on Marihuana and Drug Abuse, 
known colloquially as the Shafer Commission, to study the health and psychological effects of 
marijuana.52  After analyzing the interrelationships between marijuana use, marijuana itself, and 
 
41 Pacula & Smart, supra note 39, at 401. 
42 Darla Mercado, These 4 States are Voting to Legalize and Tax Marijuana Sales, CNBC, (Oct. 7, 2020), 
https://www.cnbc.com/2020/10/07/f04-states-voting-to-puff-puff-pass-pot-legalization.html. See also Kyle Jaeger, 
Every Single Marijuana and Drug Policy Ballot Measure Passing on Election Day Bolsters Federal Reform, 
MARIJUANA MOMENT (Nov. 4, 2020), https://www.marijuanamoment.net/every-single-marijuana-and-drug-policy-
ballot-measure-passing-on-election-day-bolsters-federal-reform-push/. 
43 See generally WEST, supra note 13, at 9–10 (discussing the history of the Marihuana Tax Act). 
44 See Gonzales v. Raich, 545 U.S. 1, 11 (2005) (“the onerous administrative requirements, the prohibitively 
expensive taxes, and the risks attendant on compliance practically curtailed the marijuana trade.”). 
45 WEST, supra note 13, at 10–11. 
46 21 U.S.C.A. § 812(b) (West 2018). 
47 See id. 
48 Id. § 812(c). 
49 Id. § 812(b). 
50 See generally 21 C.F.R. § 1301.18 (2010) (stating protocols for research with Schedule I substances). 
51 Raich, 545 U.S. at 10. 
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marijuana as a social problem, the Commission recommended decriminalization of marijuana, 
finding that criminalization of possession for personal use [was] socially self-defeating.53  
However, President Nixon rejected the findings.54   
 
Marijuana is still today prohibited as a Schedule I controlled substance pursuant to federal law.55  
However, fifteen states and the District of Columbia have legalized recreational marijuana use,56 
and thirty-six have enacted some form of compassionate use legislation.57  The conflict between 
federal and state legality—or lack thereof—has led to confusion as to whether states that have 
legalized or decriminalized marijuana must enforce the federal policy prohibiting it.58  A widely 
accepted concept of voluntary cooperation has formed in the wake of such uncertainty; states may 
choose whether to accept the federal invitation, created through the CSA, to authorize their own 
officers to arrest for a violation of the federal marijuana policy.59 
 
However, the Trump administration has radically affected the concept of voluntary cooperation.60 
In 2009, then-Deputy Attorney General David Ogden issued a memorandum informing federal 
prosecutors that prosecution of individuals lawfully using marijuana for serious illnesses was an 
inefficient use of resources.61  Former Deputy Attorney General James M. Cole followed up with 
a memorandum in 2013, allowing states to enforce their own decriminalization structures and 
advising law enforcement to enforce the CSA only when the use, possession, or distribution of 
marijuana threatened to cause harm specified in the memorandum.62  However, under the Trump 
administration, Attorney General Jeff Sessions rescinded all previous guidance and effectively 
mandated federal law enforcement to enforce the CSA against all marijuana use, regardless of 
whether a state has adopted the decriminalization structure.63  
 
In 2019, House and Senate members in the 116th Congress introduced a number of bills proposing 
changes in marijuana policy.64  H.R. 2093, also known as the Strengthening the Tenth Amendment 
 
53 Id. at ch. 5; see Michael Vitiello, Legalizing Marijuana and Abating Environmental Harm: An Overblown 
Promise?, 50 U.C. DAVIS L. REV. 773, 784 (Dec. 2016). 
54 EMILY DUFTON, GRASS ROOTS: THE RISE AND FALL AND RISE OF MARIJUANA IN AMERICA, 54 (2017). 
55 21 U.S.C.A. § 812(c)(1) (West 2018). 
56 Mercado, supra note 42. 
57 Katherine Berger, ABCs and CBD: Why Children with Treatment-Resistant Conditions Should Be Able to Take 
Physician-Recommended Medical Marijuana at School, 80 OHIO ST. L.J. 309, 324 (2019). See also State Medical 
Marijuana Laws, NAT. CON. STATE LEGS., https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx 
(last visited Nov. 11, 2020).  
58 See generally Callaghan v. Darlington Fabrics Corp., No. PC-2014-5680, 2017 WL 2321181, at *13–*15 (R.I. 
Super. May 23, 2017) (discussing preemption). 
59 See Todd Grabarsky, Conflicting Federal and State Medical Marijuana Policies: A Threat to Cooperative 
Federal, 116 W. VA. L. REV. 1, 18 (2013). 
60 See Memorandum from Att’y Gen. Jefferson B. Sessions to U.S. Att’ys (Jan. 4, 2018), https://www.justice.gov/op
a/press-release/file/1022196/download. 
61 Memorandum from Deputy Att’y Gen. David W. Ogden to Selected U.S. Att’ys (Oct. 19, 2009), https://www.justi
ce.gov/opa/press-release/file/1022196/download. 
62 Memorandum from Deputy Att’y Gen. James M. Cole to U.S. Att’ys (Aug. 29, 2013), https://www.justice.gov/iso
/opa/resources/3052013829132756857467.pdf. 
63 Memorandum from Att’y Gen. Jefferson B. Sessions to U.S. Att’ys, supra note 60. 
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Through Entrusting States (STATES) Act, proposes an amendment to the CSA that protects states’ 
ability to enact marijuana policies.65  Similarly, the House has introduced H.R. 127.66  This 
bipartisan act, known as the Compassionate Access, Research Expansion, and Respect States 
(CARERS) Act of 2019, proposes “[t]o extend the principle of federalism to state drug policy, 
provide access to medical marijuana, and enable research into the  medicinal properties of 
marijuana.”67  While the current federal policy regarding marijuana is a clear prohibition, the 
matter is becoming a nationally recognized issue with support from both major parties.68  
Therefore, it remains to be seen as to whether that policy will change. 
 
Prior to 1996, all fifty states prohibited marijuana.69  In 1996, however, California became the first 
state to decriminalize marijuana for medical use.70  Alaska, Oregon, and Washington did the same 
in 1998.71  Over the next ten years, ten states decriminalized medical marijuana.72  In 2012, 
Colorado made history as the first state to legalize recreational marijuana.73  As of 2020, thirty-
four states have decriminalized marijuana for medicinal use.74  Alaska, Arizona, California, 
Colorado, Illinois, Maine, Massachusetts, Michigan, Mississippi, Montana, Nevada, New Jersey, 
Oregon, South Dakota, Washington, Vermont, and the District of Columbia have legalized 
marijuana for both medical and recreational use.75 
 
Texas is one state that has yet to decriminalize marijuana.76  However, the Texas Legislature 
implemented the Compassionate Use Act in 2015.77  This bill allows registered physicians to 
 
65 H.R. 2093. 
66 H.R. 127. 
67 Id.; accord Press Release, Cong. Steve Cohen, Lawmakers Introduce Bipartisan Med. Marijuana Bill (Jan. 3, 
2019), https://cohen.house.gov/media-center/press-releases/lawmakers-introduce-bipartisan-medical-marijuana-bill. 
68 Andrew Daniller, Two-Thirds of Americans Support Marijuana Legalization, PEW RESEARCH CTR. (Nov. 14, 
2019), https://www.pewresearch.org/fact-tank/2019/11/14/americans-support-marijuana-legalization/. 
69 Alex Kreit, Marijuana Legalization and Nosy Neighbor States, 58 B.C. L. REV. 1059, 1059 (2017). 
70 Calandrillo & Fulton, supra note 21, at 210. 
71 Id. at 211–13 tbl. 1. 
72 Id. 
73 See id. (showing that Washington also legalized recreational marijuana in the same year). 
74 Id. at 210; Jaeger, supra note 42. 
75 Id. at 210; CBS NEWS & ASSOCD. PRESS, Illinois Becomes 11th State to Legalize Recreational Marijuana, CBS 
NEWS (June 25, 2019, 2:05 PM), https://www.cbsnews.com/news/illinois-recreational-marijuana-governor-legalizes-
governor-j-b-pritzker-signs-bill-today-2019-06-25/. See also Kyle Jaeger, Every Single Marijuana And Drug Policy 
Ballot Measure Passing On Election Day Bolsters Federal Reform, MARIJUANA MOMENT (Nov. 4, 2020), 
https://www.marijuanamoment.net/every-single-marijuana-and-drug-policy-ballot-measure-passing-on-election-
day-bolsters-federal-reform-push/.  
76 See Mercado, supra note 42. As of November 10, 2020, Texas legislators have pre-filed fifteen bills related to the 
decriminalization and legalization of marijuana. Tracking: Texas Marijuana Policy, 87th Legislative Session, 
TEXANS FOR RESPONSIBLE MARIJUANA POLICY, 
http://www.texasmarijuanapolicy.org/txmj21/?fbclid=IwAR2R3tXTHELUwbTVxZb7Dyy-307KsHnl5mJHuEP2Sc-
J68nGwib7HjqgZsQ (last visited Nov. 11, 2020).  
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prescribe cannabis containing low percentages of THC to patients suffering from epilepsy.78  The 
Act defines low-THC cannabis as containing less than 0.5% THC on a dry-weight basis.79  House 
Bill 3703, enacted in 2019, expands the application of the Compassionate Use Act to additional 
medical disorders.80  “Incurable neurodegenerative disease, terminal cancer, a seizure disorder, 
multiple sclerosis, spasticity, amyotrophic lateral sclerosis, and autism” now qualify as covered 





Along with marijuana, the 1937 Marihuana Tax Act banned hemp from the United States 
markets.83  In 1970, the CSA included hemp as an illegal substance and was subsequently 
reinforced by the Drug Enforcement Agency’s (DEA) interpretation of its language.84  The CSA 
classified “any material, compound, mixture, or preparation, which contains . . . THC” as a 
Schedule I controlled substance.85  However, it simultaneously excluded “mature stalks of 
[Cannabis sativa] plant” from its definition of marijuana.86  The DEA, utilizing its regulatory 
authority, interpreted the former language to include hemp as a Schedule I substance.87  Therefore, 
the government had prohibited all forms of cannabis pursuant to the CSA until the passage of the 
2018 Farm Bill.88 
 
Before the 2018 Farm Bill, the 2014 Farm Bill served as the first move away from hemp 
prohibition pursuant to federal law.89  The bill instituted an exception for hemp production by 
allowing farmers to grow hemp under specified conditions.90  It established a definition of hemp 
and narrowly allowed its production; however, hemp was still categorized as a Schedule I drug, 
along with all other forms of cannabis.91  The bill enacted a form of protection for hemp growers 
in the Hemp Pilot Programs, which allowed those who registered under a state’s hemp research 
program to cultivate the plant.92  Nevertheless, hemp remained illegal if produced in violation of 
the Farm Bill’s requirements.93  
 
78 TEX. OCC. CODE ANN. § 169.003(3)(A)(i). 
79 Id. § 169.001(3). 
80 Id. § 169.003. 
81 Id. 
82 See id. 
83 Shannon Smith, Hemp on the Horizon: The 2018 Farm Bill and the Future of CBD, 98 N.C.L. REV. ADDENDUM 
35, 40 (2020). 
84 Id. at 41. 
85 Id. 
86 Id. 
87 See id. 
88 See id. at 41–42. 
89 Id. at 42. 
90 Agricultural Act of 2014, Pub. L. No. 133-79, § 7606, 128 Stat. 649, 912-13 (codified as amended at 7 U.S.C. 
§ 5940 (2018)). 
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The 2018 Farm Bill expanded the realm of hemp cultivation established by the 2014 Farm Bill.94  
It defined industrial hemp as cannabis containing 0.3% THC on a dry-weight basis,95 adopted from 
a Canadian scientific study that sought to differentiate between two strains of marijuana.96  The 
researchers themselves had “arbitrarily adopt[ed] a concentration of 0.3% THC . . . as a guide to 
discriminating [between hemp and marijuana]” during the study.97  Additionally, the bill legalized 
hemp production across the board and declassified it as a Schedule I drug.98  It established a federal 
framework for hemp regulation and enforcement by transferring the regulatory authority to the 
U.S. Department of Agriculture.99  However, while the 2018 Farm Bill removed hemp from 
Schedule I status, it did not federally legalize CBD.100  Instead, CBD is legal if, and only if, the 
hemp from which it is derived complies with federal and state regulations and is produced by a 
licensed cultivator.101  If the hemp in question does not comply with such requirements, the CBD 
product is deemed a Schedule I drug.102  
 
In 2019, the Texas Legislature approved the passage of House Bill 1325.103  The bill legalized the 
use and production of hemp and hemp-derived products, such as CBD oil, and mirrored the federal 
statute in defining hemp.104  The Texas Legislature had previously emphasized that it had no 
intention of decriminalizing marijuana;105 H.B. 1325 pertains exclusively to hemp and hemp-
derived products.106  
 
IV. Lack of Proper Testing 
 
When H.B. 1325 legalized hemp and its derivatives, it created challenges in differentiating 
between hemp and marijuana.  Such challenges carry implications in both criminal and 
employment contexts.  This Part explores how law enforcement and employers must contend with 
these difficulties following the bill’s enactment. 
 
 
94 See id. 
95 Agricultural Improvement Act of 2018 § 297A, 7 U.S.C. § 1639o (2018). 
96 See Ernest Small & Arthur Cronquist, A Practical and Natural Taxonomy for Cannabis, 25 TAXON 4, 405, 408 
(Aug. 1976). 
97 Id. 
98 Agricultural Improvement Act § 12619. 
99 See Smith, supra note 83, at 42. 
100 Berger, supra note 57, at 324. 
101 John Hudak, The Farm Bill, Hemp Legalization and the Status of CBD: An Explainer, BROOKINGS INST. (Dec. 
14, 2018), https://www.brookings.edu/blog/fixgov/2018/12/14/the-farm-bill-hemp-and-cbd-explainer/.  
102 Id. 
103 See generally H.R. 1325, 86th Leg., Reg. Sess. (Tex. 2019). 
104 See id.; 7 U.S.C. § 1639o(1) (2018). 
105 On November 10, 2020, Texas legislators pre-filed three proposals to legalize marijuana. See HJR 13, 87th Leg. 
Reg., Reg. Sess. (Tex. 2020); S.B. 14087th Leg. Reg., Reg. Sess. (Tex. 2020); H.B. 447, 87th Leg., Reg. Sess. (Tex. 
2020). 
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A. Law Enforcement 
 
While advocates have lauded H.B. 1325 as a step forward for both agricultural and legalization 
interests, it has simultaneously created confusion with respect to enforcement.107  Prior to the 
passage of the bill, the marijuana testing process simply consisted of identifying hairs on marijuana 
flowers and using a cannabinoid-detecting test strip.108  However, crime laboratories must now 
establish the precise percentage of THC in the suspected substance to determine whether it is 
marijuana or hemp.109  Prosecutors and forensic experts have raised concerns that public 
laboratories lack the proper testing equipment while well-equipped laboratories impose high 
costs.110  In fact, the president of the Houston Forensic Science Center has identified only two 
laboratories in the nation with such capabilities, and both are privately owned.111  
 
Texas law enforcement now faces both financial and practical implications of the bill.  Prosecutors 
must contend with the possibility that they may be required to compensate the aforementioned 
private labs to run the tests and testify to the results at trial.112  Given that marijuana offenses made 
up twenty-four percent of the Texas criminal docket in 2018, the potential financial impact on the 
state is staggering.113  Practically, there is a potential for tremendous backlogging of marijuana 
cases.114  In 2018, marijuana-related arrests in the United States totaled 663,367.115  In Texas 
specifically, the criminal docket contained 113,452 active marijuana possession  cases.116  
Considering these numbers, it is unrealistic to expect two crime labs to handle marijuana testing 
for the entire state of Texas, particularly when accounting for other states that have not 
decriminalized marijuana.117   
 
Prosecutors across Texas have voiced such concerns, with many having dropped misdemeanor and 
even felony possession charges.118  Prosecutors fear that the bill has eliminated the possibility of 
using circumstantial evidence: law enforcement can no longer rely on using the smell and 
 






113 Off. Of Court Admin., Annual Statistical Report for the Texas Judiciary: Fiscal Year 2018, TEX. JUD. COUNCIL, 
1, 31 https://www.txcourts.gov/media/1443455/2018-ar-statistical-final.pdf (last visited Oct. 26, 2020). 
114 Bogel-Burroughs, supra note 10.  
115 See Uniform Crime Reporting, 2018 Crime in the United States, FBI, https://ucr.fbi.gov/crime-in-the-
u.s/2018/crime-in-the-u.s.-2018/topic-pages/persons-arrested (last visited Oct. 26, 2020) (stating that, of 1,654,282 
drug-related arrests, 3.3% were related to sale/manufacturing of marijuana and 36.8% were related to marijuana 
possession). 
116 Off. Of Court Admin., supra note 113, at 18. 
117 See generally Bogel-Burroughs, supra note 10 (stating that there are only two accredited labs in Texas that can 





The Budding Hemp Industry: The Effect of Texas House Bill 1325 on  




appearance of marijuana as evidence because hemp has similar characteristics.119  The primary 
distinction between marijuana and hemp lies in the THC concentration; an inability to test this 
difference may hinder the conclusion that a suspected substance is marijuana “beyond a reasonable 
doubt.”120 
 
In response to such dismissals and concerns, Texas Governor Greg Abbott, Lieutenant Governor 
Dan Patrick, Speaker of the Texas House of Representatives Dennis Bonnen, and Texas Attorney 
General Ken Paxton issued a letter to Texas district and county attorneys.121  It stated that attorneys 
have misunderstood H.B. 1325 and advised them that lab tests are not the exclusive method of 
proving marijuana possession cases.122  It went on to emphasize the acceptability of circumstantial 
evidence.123  Additionally, the letter stated that companies and labs were developing THC 
concentration tests prior to the passage of H.B. 1325, and that costs of THC tests would decline as 
companies enter the market for testing.124  The letter reminded attorneys that marijuana remained 
illegal and that they were responsible for carrying out the law.125 
 
Some Texas counties have proceeded to charge and prosecute marijuana cases as they had done 
prior to the adoption of the bill.126  However, district attorneys in Travis and Harris counties have 
reaffirmed their plans to require lab testing for low-level marijuana cases in order to prove guilt 
beyond a reasonable doubt.127  Until labs possess the requisite testing equipment to determine THC 
concentration levels, many prosecutors are postponing prosecution of marijuana offenses as 
advised by the Texas District and County Attorneys Association.128  Until Texas can establish a 





119 See id. See generally Big Sky Scientific LLC v. Idaho State Police, No. 1:19-cv-00040-REB, 2019 WL 438336 at 
*3 (D. Idaho Feb. 2, 2019) (describing a defendant who was arrested while transporting 7,000 pounds of industrial 
hemp and charged with marijuana trafficking). 
120 See generally Bogel-Burroughs, supra note 10 (stating that labs are now required to determine the concentration 
of THC in seized substances due to the new legal distinction between marijuana and hemp).  





126 Jolie McCullough & Alex Samuels, This Year, Texas Passed a Law Legalizing Hemp. It Also Has Prosecutors 
Dropping Hundreds of Marijuana Cases, TEX. TRIBUNE (July 3, 2019), https://www.texastribune.org/2019/07/03/te
xas-marijuana-hemp-testing-prosecution/.   
127 Id. 
128 Interim Update: Hemp, TEX. DIST. & CTY. ATT’YS ASS’N (June 24, 2019), 
https://www.tdcaa.com/legislative/interm-update-hemp/. 
129 See generally Boulette Golden & Marin LLP, Changing Laws, Attitudes Pushing Employers to Explore 
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A 2018 study found that Dallas and Houston were among the top ten cities in the nation with the 
highest amount of jobs that require drug testing.130 Texas employers are likely to encounter 
comparable levels of difficulty in determining whether employees are using marijuana or CBD 
solely on the basis of drug test results.131  The current inability to test CBD creates tension between 
permitted state use and employers’ ability to regulate the conduct of their employees inside and 
outside the workplace.  
 
Urinalysis testing is one of the most common methods used in the workplace.132  However, such 
tests merely establish drug use and cannot indicate levels of intoxication.133  In fact, research 
indicates that unintentional inhalation of marijuana smoke may be sufficient to trigger a positive 
urinalysis test result.134  The existing unreliability of drug testing methods faces compounded 
uncertainty in light of H.B. 1325.135  In addition, employers have given no indication that they 
intend to change their existing testing procedures.136  
 
Therefore, employers now must contend with drug testing employees and establishing whether 
positive test results are due to marijuana or CBD use.137  For example, a former federal agent in 
Texas failed a drug test that returned a positive result for marijuana despite the fact that he had 
used CBD oil, not recreational marijuana, to alleviate back pain.138   Conventional drug testing 
methods are able to detect the presence of THC but cannot differentiate between marijuana and 
CBD.139  Accordingly, Texas law enforcement and employers are currently experiencing the same 
heightened burden for drug testing. 
 
 
130 An Analysis of Employer Drug Testing in the United States, AM. ADDICTION CTRS., 
https://americanaddictioncenters.org/learn/analysis-employer-drug-testing/ (last visited on Oct. 26, 2020). 
131 See Establishment of a New Drug Code for Marihuana Extract, 81 Fed. Reg. 90,194, 90,195 (Dec. 14, 2016) 
(codified at 21 C.F.R. § 1308.11(d)) (in the comments to the proposed rule, the DEA states, “Although it might be 
theoretically possible to produce a CBD extract that contains absolutely no amounts of other cannabinoids, the DEA 
is not aware of any industrially-utilized methods that have achieved this result.”).  
132 Kathleen Harvey, Protecting Medical Marijuana Users in the Workplace, 66 CASE W. RES. L. REV. 209, 215 
(2015). 
133 Anne M. Rector, Use and Abuse of Urinalysis Testing in the Workplace: A Proposal for Federal Legislation 
Limiting Drug Screening, 35 EMORY L.J. 1011, 1019–20 (1986). 
134 Id. at 1020. 
135 See Scott Friedman & Jack Douglas Jr., His Back Hurt So He Tried CBD – It Cost Him His Job, NBC DALLAS-
FORT WORTH (Sept. 23, 2019), https://www.nbcdfw.com/investigations/His-Back-Hurt-So-He-Tried-CBD----It-
Cost-Him-His-Job-561139041.html.  
136 See generally Mitch Mitchell, Don’t Get Lost in the Weeds. Using Legal CBD Products in Texas Could Cost You 
a Job, FORT WORTH STAR-TELEGRAM (Sept. 19, 2019), https://www.star-telegram.com/news/business/article23497
2167.html.  
137 Id.; see Friedman & Douglas, supra note 135. 
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V. Employment Protection 
 
This Part highlights relevant provisions of the ADA and its state counterpart, the Texas Labor 
Code, to fully illustrate the requirements that employees and applicants must meet in order to 
ensure employment protection, in addition to the type of drug policies employers may impose on 
their employees.  This Part describes the tension between cannabis use and the ADA—specifically, 
the effect of marijuana usage on an employee’s ability to implicate protection under either the 
ADA or Texas state employment laws.  However, the primary focus of this Part is the current lack 
of CBD regulation, the FDA’s position regarding CBD products, and possible employment 
protection for users of CBD who inadvertently test positive for THC.  By evaluating these factors 
in totality, this Part emphasizes the current precariousness of employee protection and employer 




The Americans with Disabilities Act (ADA) provides protection against employment 
discrimination at the federal level.140  Congress enacted the ADA to establish and enforce standards 
that eliminated employment-based discrimination against individuals with disabilities.141  The Act 
defines “disability” as “a physical or mental impairment that substantially limits one or more major 
life activities of an individual, a record of such impairment, or an individual who is regarded as 
having such an impairment.”142  The statute provides examples of such major life activities, such 
as “hearing, seeing, sitting, standing, eating, thinking, and communicating.”143  
 
A person claiming that they have such an impairment must demonstrate that they have been subject 
to an action prohibited under the ADA because of an actual or perceived impairment, regardless 
of whether the impairment limits or is perceived to limit a major life activity.144  The claimed 
impairment must last or be expected to last at least six months.145  An impairment that is “episodic 
or in remission” must “substantially limit a major life activity when active” in order to qualify 
under the ADA.146 
 
The ADA prohibits employment-based discrimination against a qualified individual by a covered 
entity with respect to job application procedures, the hiring, advancement, or termination of 
 
140 Elisa Y. Lee, An American Way of Life: Prescription Drug Use in the Modern ADA Workplace, 45 COLUM. J.L. 
& SOC. PROBS. 303, 304 (2011) (“Congress passed the Americans with Disabilities Act . . . which expanded the 
scope of civil rights protections for individuals with disabilities . . . .”). 
141 See 42 U.S.C. § 12101 (2012). 
142 42 U.S.C.A § 12102(1) (2009). 
143 Id. § 12102(2). 
144 Id. § 12102(3)(A). 
145 Id. § 12102(3)(B). 
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employees, compensation, job training, and other terms of employment.147  Such “qualified 
individuals” are those who, with or without reasonable accommodation, can perform the essential 
job functions of the position at issue.148  A “covered entity” is defined as an “employer, 
employment agency, labor organization, or joint-labor management committee.”149  
 
The statute defines an “employer” as a person who participates in an industry that affects 
commerce and has at least fifteen employees, excluding “United States government-owned 
corporations and bona fide private membership clubs.”150  A covered entity is not obligated to 
accommodate disabilities without an employee’s request or if doing so would pose an undue 
hardship upon the employer.151  If an employee requests a reasonable accommodation, the covered 
entity may require documentation before granting it.152  Additionally, a covered entity may not ask 
job applicants about the “existence, nature or severity of a disability.”153 
 
The ADA defines the “illegal use of drugs” as the “use of drugs considered unlawful under the 
Controlled Substances Act,” but excludes the use of a drug “taken under supervision by a licensed 
health care professional or other uses authorized by the Controlled Substances Act.”154  The ADA 
allows covered entities to entirely prohibit the use of illegal drugs and alcohol at the workplace or 
prohibit employees from being under the influence of drugs and alcohol at the workplace.155  
Covered entities are required to provide notice of policies to applicants and employees.156 
 
The ADA does not protect an otherwise qualified individual with a disability who currently uses 
illegal drugs, “when the covered entity acts on the basis of such use.”157  Therefore, if an employer 
discriminates against a qualified individual with a disability, the ADA will not protect that 
individual if the discriminatory act is based on the individual’s use of illegal drugs pursuant to the 
CSA.158  However, the ADA does protect individuals who are mistakenly regarded as using drugs 
but are not in fact doing so.”159  Interestingly, this language indicates that the ADA formulated an 
exception for individuals who could disprove allegations of illegal drug use, long before the 
enactment of the Farm Bill.  Theoretically, if an individual can prove that his alleged marijuana 
use was in fact CBD, the ADA’s exception would apply—particularly because the ADA’s scope 
is limited to the CSA, not the Farm Bill or state-approved uses.160 
 
147 Id. § 12112(a). 
148 Id. § 12111(8). 
149 Id. § 12111(2). 
150 Id. § 12111(5). 
151 Facts about the Americans with Disabilities Act, EEOC, https://www.eeoc.gov/eeoc/publications/fs-ada.cfm (last 
visited on Oct. 26, 2020) [hereinafter Facts]. 
152 See Templeton v. Neodata Servs., Inc., 162 F.3d 617, 619 (10th Cir. 1998) (holding that employee’s failure to 
provide medical information about her condition precluded her claim that her employer violated the ADA). 
153 See Facts, supra note 151. 
154 § 12111(6)(A). 
155 Id. § 12114(c)(1)–(2). 
156 Id. § 12115. 
157 Id. § 12114(a). 
158 Id. 





The Budding Hemp Industry: The Effect of Texas House Bill 1325 on  







Texas state law prohibits disability-based employment discrimination pursuant to Chapter 21 of 
the Texas Labor Code.161  Chapter 21 is consistent with many ADA provisions and contains similar 
language.162  However, there are differences between Chapter 21 and the aforementioned ADA 
provisions.163  
 
Chapter 21 follows the ADA standard by withholding protection against employment-based 
discrimination for an individual who “currently uses or possesses a controlled substance as defined 
in Schedules I and II of . . . the Controlled Substances Act.”164  It similarly carves out an exception 
for authorized use of a prohibited Schedule I drug.165  However, it also inadvertently broadens the 
scope of protection to include Schedule II drugs authorized by a health care professional “or 
otherwise authorized by the [CSA] or any other federal or state law.”166  
 
While the Texas statute deviates from the ADA by permitting the authorized use of a wider scope 
of drugs and allowing laws other than the CSA to define illegal drugs, it mirrors the ADA in its 
lack of protection for individuals who test positive for THC because Texas has not decriminalized 
marijuana.167  Therefore, for purposes of CBD use, Chapter 21 reflects the requirements of the 
ADA in order for a CBD user to invoke its protection.168  So long as an individual can prove the 
substance in question does not contain THC, they may invoke protection against discrimination 
pursuant to Chapter 21. 
 
C. Cannabis Use 
 
As marijuana is currently prohibited as a Schedule I controlled substance under the CSA, the ADA 
will not protect an individual who uses marijuana.169  Therefore, an otherwise qualified individual 
may not bring a claim under the ADA for discrimination based on medical marijuana use, even in 
a state that has decriminalized such use.170  While the ADA offers marijuana users no protection, 
 
161 TEX. LAB. CODE ANN. § 21.001(4) (West 2019).  
162 El Paso v. Vasquez, 508 S.W.3d 626, 637 (Tex. App. 2016). 
163 See generally id. at 641 (“We cannot conclude that Chapter 21 [of the Texas Labor Code] and the ADA are 
analogous for purposes of creating a disclosure of confidential health information cause of action.”). 
164 TEX. LAB. CODE ANN. § 21.120(a). 
165 Id. 
166 Id. 
167 Compare 42 U.S.C.A. §12114(a)–(b), with TEX. LAB. CODE ANN. § 21.120(a). 
168 Compare 42 U.S.C.A. §12114(a)–(b), with TEX. LAB. CODE ANN. § 21.120(a). 
169 21 U.S.C. § 812(c) (1970); 42 U.S.C.A. § 12111(6)(a). 
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employees may find relief through enforcement of state laws.171  Courts have generally held that 
while marijuana is federally prohibited, state laws authorizing the use of marijuana are not 
federally preempted.172 
 
Questions regarding employment rights and CBD-based products surfaced following the passage 
of the 2018 Farm Bill.173  Many employers are now uncertain whether the legalization of hemp-
derived products will affect their ability to enforce drug policies; employees are unsure what their 
rights will be regarding CBD use and whether the ADA will protect such rights.174  In Texas, H.B. 
1325 amplifies these questions.175  
 
Following the 2018 Farm Bill’s declassification of hemp as a controlled substance, the ADA 
exception for individuals who engage in illegal drug use does not apply to those using CBD.176  
Therefore, the ADA would presumably protect an otherwise qualified individual who uses CBD 
to ameliorate a disability.177  At the same time, a caveat remains: the substance may not contain 
more than 0.3% THC.178  This poses further complications due to the lack of regulation regarding 
CBD products, coupled with stringent FDA restrictions on current products.179  
 
1. Unregulated CBD Concentrations 
 
As hemp-derived CBD is not yet regulated, CBD concentrations in consumer products lack 
standardization.180  For purposes of federal and Texas state law, hemp-derived products are merely 
required to contain less than 0.3% THC.181  There is no standard for CBD concentration.182  
Consumers and regulators alike have no method of discerning just how much CBD a product 
contains.  Companies face legal challenges both with the FDA and in courts due to inconsistency 
between claimed and actual levels of CBD.183  Therefore, consumers lack both actual knowledge 
 
171 See Wild v. Carriage Funeral Holdings, Inc., 205 A.3d 1144, 1147 (N.J. Super. Ct. App. Div. 2019) (holding that 
although the New Jersey Compassionate Use Act refused to require employment accommodations for users of 
medical marijuana, employers were not immunized from such requirements imposed elsewhere). 
172 See Barbuto v. Advantage Sales & Mktg., LLC, 78 N.E.3d 37, 45 (Mass. 2017); In re D.M., 444 P.3d 834, 837 
(Colo. App. 2019). 
173 See generally Lisa L. Gill, Can You Take CBD and Pass a Drug Test?, CONSUMER REPORTS (May 15, 2019), 
https://www.consumerreports.org/cbd/can-you-take-cbd-and-pass-a-drug-test/.  
174 See id. 
175 See Friedman & Douglas Jr. supra note 135. 
176 U.S.C.A. 42 § 12114(a) (West 2009); see id. § 12111(6)(a); supra text accompanying notes 99–101. 
177 See § 12114(a). 
178 Agricultural Improvement Act of 2018 § 297A, 7 U.S.C. § 1639o(1) (2018). 
179 See generally Cindy Krischer Goodman, Buyer Beware: CBD Products Could Be This Century’s Snake Oil, S. 
FLA. SUN SENTINEL (Jun. 07, 2019), https://www.sun-sentinel.com/health/fl-ne-cbd-regulation-20190607-
4upiw7zacfgt5k24glrvxqiswu-story.html (discussing the CBD industry’s lack of regulations and resulting concerns).  
180 Grinspoon, supra note 12.  
181 Agricultural Improvement Act § 297A; H.R. 1325, 86th Leg., Reg. Sess. (Tex. 2019). 
182 Grinspoon, supra note 12.  
183 See Warning Letters and Test Results for Cannabidiol-Related Products, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/news-events/public-health-focus/warning-letters-and-test-results-cannabidiol-related-products 
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of what they are consuming and clarity regarding drug-testing results.  Although CBD products 
are required to contain less than 0.3% THC, there is no guarantee of compliance.184   
 
The inability to discern CBD content has led to inconsistency in labeled dosages of CBD 
products.185  A 2017 scientific study found that about seventy percent of CBD products sold online 
were incorrectly labeled, with twenty-six percent of the products containing a lower CBD 
concentration than the labeled dosage indicated.186  In addition to the mislabeling of CBD 
concentration, a number of the tested products contained a mean of 1.18% THC—a concentration 
high enough to produce psychoactive effects, and that exceeds the federal- and state-mandated 
limit.187  For consumers, this entails the possibility that lawful purchase and use of a CBD product 
could result in a positive drug test, in addition to potentially severe health effects, such as adverse 
reactions with other drugs or abnormalities in the liver.188  
 
The lack of CBD regulation implicates consumers’ inability to ensure safety even if they adhere 
to the stipulations of the law.  The uncertainty of CBD concentration in products means that there 
is currently no consistent answer for drug testing: will a person test positive for THC, even if he 
purchases a CBD product under the assumption that it does not contain THC?  If such a product is 
CBD isolate, then the answer is likely no.189  On the other hand, full-spectrum CBD is generally 
regarded as more effective than CBD isolate because of the “entourage effect” in which the 
different cannabinoids work together to increase effectiveness of the substance.190   
 
Thus, consumers are likely to opt for full-spectrum CBD and run the risk of ingesting more THC 
than they had expected, based on the information on the product label.191  Such risk is compounded 
when considered in combination with how THC may appear in a urinalysis test up to thirty days 
after initial use and in a hair analysis test for up to ninety days after initial use.192  While some 
authorities have stated that any THC present in CBD products would be minimal and unlikely to 
 
2019) (plaintiff employees relied on a CBD product’s claim of zero percent THC concentration and subsequently 
failed drug tests, resulting in termination). 
184 See Horn, 383 F. Supp. 3d at 129 (“Defendant’s own testing revealed that the product contained detectible 
amounts of THC.”).  
185 Marcel O. Bonn-Miller et al., Labeling Accuracy of Cannabidiol Extracts Sold Online, 318 JAMA 1708, 1708 
(Nov. 7, 2017), https://jamanetwork.com/journals/jama/fullarticle/2661569.  
186 Id.  
187 Id. 
188 Marilyn A. Huestis et. Al., Cannabidiol Adverse Effects and Toxicity, 17 CURRENT NEUROPHARMACOLOGY 974, 
975, 977, 981 (2019) (stating that CBD pharmacology has the potential for adverse effects and drug-drug 
interactions, including toxicity and increased liver function). See generally Bonn-Miller et al., supra note 185.  
189 See generally Carter & Vandergriendt, supra note 32 (stating that CBD isolate does not contain additional 
compounds and therefore should not contain THC).  
190 What Does Full Spectrum Mean?, EXTRACT LABS (July 31, 2019), https://www.extractlabs.com/cbd-
guides/what-does-full-spectrum-mean/. 
191 See generally id. 
192 Scott E. Hadland and Sharon Levy, Objective Testing – Urine and Other Drug Tests, 25 CHILD & ADOLESCENT 
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cause a positive drug test, the current lack of regulation breeds uncertainty regarding actual THC 
content, and thus implicates the possibility of positive drug test results.193  In light of H.B. 1325, 
Texas employers now must contend with such uncertainty as CBD products enter the state market 
without regulation. 
 
2. FDA Restrictions 
 
Congress explicitly reserved the authority to regulate products containing cannabis and cannabis-
derived substances (cannabis-derived products) to the Food and Drug Administration in the 2018 
Farm Bill.194  The FDA therefore is responsible for enforcing the law as well as establishing 
regulations for cannabis-derived products.195  The FDA holds cannabis-derived products to the 
same requirements as other FDA-regulated products.196  The agency requires cannabis-derived 
products that are marketed with a therapeutic benefit claim or disease claim197 to obtain FDA 
approval for their intended use before entering interstate commerce.198 
 
The FDA defines a “dietary supplement” as a “product . . . intended to supplement the diet that 
bears or contains one or more” of a specified list of dietary ingredients.”199  In contrast, a “drug” 
is defined as an “articles intended for use in the diagnosis, cure, mitigation, or prevention of 
disease,” and “articles . . .  intended to affect the structure or function of the body.”200  However, 
the FDA has explicitly excluded THC and CBD products from the definition of “dietary 
supplements.”201  Cannabis-derived products intended for disease-related use are instead 
considered new drugs,202 and may not be marketed in the United States without undergoing the 
FDA drug approval process for human use.203  Currently, the FDA prohibits the introduction of 
food containing added CBD or THC into the market, as well as the marketing of CBD or THC 
products as, or as component part of, dietary supplements.204  
 
 
193 See generally Gill, supra note 173. 
194 Scott Gottlieb, Statement from FDA Commissioner Scott Gottlieb, M.D., on Signing of the Agricultural 
Improvement Act and the Agency’s Regulation of Products Containing Cannabis and Cannabis-Derived 






199 21 U.S.C.A. § 321(ff)(1) (West 2016). 
200 See id. § 321(g)(1) (2016). 
201 FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD), U.S. FOOD & 
DRUG ADMIN., https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-
products-including-cannabidiol-cbd#dietarysupplements (last visited Oct. 28, 2020). 
202 Gottlieb, supra note 194; see § 321(p) (defining “new drug” as one whose composition is not generally 
recognized or has been investigated and deemed safe for use but has not been used to a material extent).  
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In June 2018, the FDA “approved [the drug] Epidiolex . . . for the treatment of seizures associated 
with two rare and severe forms of epilepsy.”205  Epidiolex is the first, and currently the sole, FDA-
approved drug containing a cannabis-derived substance.206  Presently, the presence of any other 
drug, food product, or dietary supplement containing CBD in interstate commerce violates the 
Food, Drug, and Cosmetic Act.207  The FDA’s focus, nevertheless, is on the “marketing of CBD 
products that make unsubstantiated therapeutic claims” without new drug approval.208  Thus, the 
FDA’s main enforcement efforts have primarily constituted the issuance of warning letters to non-
compliant sellers of CBD products.209  Although the presence of food and dietary drugs containing 
CBD in interstate commerce is currently unlawful, the FDA’s focus is on CBD products that are 
marketed with unsubstantiated therapeutic claims.210  As Epidiolex is presently the only FDA-
approved cannabis-derived medical treatment on the market, no other drugs containing CBD may 
be sold legally.211  The FDA’s demonstrated and enumerated lack of focus on CBD products 
without such marketing, however, contributes to the current uncertainty surrounding the actual 
benefits and contents of such products.212  
 
3. Effect of Cannabis Use 
 
While the ADA does not protect marijuana users from employment discrimination on the basis of 
disability, it may protect CBD users so long as the CBD product does not contain THC.213  A 
qualified individual must have a disability, use CBD to ameliorate such a disability, and be able to 
provide documentation to that effect.214  The ADA does not specifically require the 
accommodation to be a medication.215  Thus, the lack of FDA-approved CBD drugs is unlikely to 
bar ADA protection because a qualified individual would presumably be able to use a dietary 
supplement or food containing CBD as an accommodation.216  While such products are presently 
illegal at the federal level and will likely remain so until the FDA deems otherwise, the ADA only 
 
205 Press Release, U.S. FOOD & DRUG ADMIN., supra note 9.  
206 Id. 
207 Hemp Production and the 2018 Farm Bill: Hearing Before the Senate Comm. On Agriculture, Nutrition, & 
Forestry, 116th Cong. 11 (2018) (statement of Amy Abernethy, Principal Deputy Comm’r of the Office of the 
Comm’r, Food & Drug Admin., U.S. Dep’t of Health & Human Servs.). 
208 Id. at 51. 
209 Warning Letters and Test Results for Cannabidiol-Related Products, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/news-events/public-health-focus/warning-letters-and-test-results-cannabidiol-related-products 
(last updated Oct. 9, 2019). 
210 See generally Hemp Production and the 2018 Farm Bill: Hearing Before the Senate Comm. On Agriculture, 
Nutrition, & Forestry, supra note 207. 
211 Id. at 49. 
212 Id. at 54. 
213 See generally 42 U.S.C.A. § 12114(a) (West 2009).  
214 See id. § 12102(1); Templeton, 162 F.3d at 619 (granting summary judgement to defendant-employer for 
Templeton’s failure to produce medical information). 
215 § 12111(9). 
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excludes illegal drug use as defined by the CSA.217  An employee therefore would likely be able 
to implicate the ADA in an employment discrimination dispute. 
 
Conversely, if the CBD contains THC, the issue becomes whether an employee who lawfully uses 
a substance to ameliorate his disability but tests positive for a substance that is illegal at both the 
state and federal levels, may access employment discrimination protections.  The ADA does not 
protect medical marijuana users due to the Schedule I classification, even though such use is 
permitted in some states.218  Therefore, employees have no federal protection against employment 
discrimination if they test positive for THC, regardless of whether they used marijuana or CBD. 
 
Similarly, Texas state laws provide no protection against employment discrimination based on 
positive results of a drug test.219  Chapter 21 of the Texas Labor Code allows employers to “[adopt] 
a policy prohibiting the employment of an individual who currently uses or possesses a controlled 
substance as defined in . . . the Controlled Substances Act . . . other than the use or possession of 
a drug taken under the supervision of a licensed health care professional or any other use or 
possession authorized by the Controlled Substances Act or any other federal or state law.”220  The 
provision may protect CBD users so long as they do not test positive for THC. 
As described above, the broadened scope encompassing “any other federal or state law” fails to 
provide additional protection because Texas has yet to decriminalize marijuana.221  Additionally, 
the Compassionate Use Act does not furnish employment protection for qualifying patients.222  
Therefore, Texas state laws mirror federal laws in that they do not provide protection against 
employment discrimination for an employee who tests positive for THC.223  
 
In light of the current state of employment discrimination laws, employers may form policies 
prohibiting the use of CBD until drug testing equipment advances.  Meanwhile, employees should 
abstain from using CBD at the risk of testing positive for THC due to the risk that employment 






217 Gottlieb, supra note 194. 
218 See James v. City of Costa Mesa, 700 F.3d 394, 397, 401 (9th Cir. 2012) (concluding that the plaintiff’s medical 
marijuana use is not protected by the ADA despite the relief she experiences and the state of California’s recognition 
of medical marijuana as an effective treatment for debilitating pain). 
219 See TEX. LAB. CODE. ANN. § 21.120 (West 2019). 
220 Id. 
221 See generally Calandrillo & Fulton, supra note 21, at 211–13 tbl.1 (showing that Texas has not decriminalized 
marijuana). 
222 See generally Texas Compassionate Use Act of 2015 § 4, TEX. OCC. CODE ANN. §§ 169.001–169.005 (West 
2019). 
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VI. Proposal for Legislative Amendment of H.B. 1325 and Regulatory 
Rules 
 
The vague languages of the ADA and Chapter 21 of the Texas Labor Code exacerbate the 
confusion surrounding protection of CBD use in the workplace.224  Employers and employees alike 
require a clear rule regarding permitted CBD use, particularly in light of the absence of reliable 
testing methods and rigorous FDA restrictions.225  This issue will likely increase with time as the 
remaining states that have not legalized CBD choose to do so. 
 
Ideally, drug testing equipment will advance such that both law enforcement and employers will 
be able to accurately differentiate between marijuana and CBD, thereby eliminating the need to 
alter employment protection policies.  Employees would then have access to protection under the 
ADA and the corresponding Texas Labor Code in the event of a dispute over CBD use.226  
Employers would be provided clarification regarding their ability to prohibit CBD use entirely.227  
 
However, such technological advances require extensive funding and time,228 which leaves Texas 
civilians and law enforcement without guidance in the interim.229  The best method to ameliorate 
the uncertainty that has followed CBD legalization is likely a combination of an amendment to 
H.B. 1325 raising the THC threshold, administrative rules requiring third-party verification on 
CBD content and state-allocated funding for enforcement, and an exception to the Texas Labor 
Code for employees who successfully prove lawful use. 230 
 
The 0.3% THC threshold was established on the basis of Dr. Ernest Small’s research study, in 
which the researchers “arbitrarily adopt[ed] a concentration of 0.3% THC . . . as a guide to 
discriminating” between hemp and marijuana.231   There is a weak basis for the 0.3% THC 
threshold, as it falls quite short from the amount required to produce the psychoactive effects. In 
fact, the present definition of hemp was adopted “because [THC] is the only one of at least 113 
different biochemical compounds produced in . . . [cannabis] that can have an intoxicating effect 
on humans.”232  Thus, the government’s primary concern is preventing THC intoxication.233  While 
 
224 See generally 42 U.S.C.A. § 12111(6)(A) (West 2009); TEX. LAB. CODE ANN. § 21.001(4). 
225 See Friedman & Douglas, supra note 135. 
226 See generally 42 U.S.C.A. § 12111(6)(A); TEX. LAB. CODE. ANN. § 21.001(4). 
227 See generally 42 U.S.C.A. §12111(6)(A); TEX. LAB. CODE. ANN. § 21.001(4). 
228 See Ryan Poppe, Bexar County Approves Purchase of Crime Lab Equipment to Test Marijuana, Hemp, TEX. 
PUB. RADIO (Sep. 4, 2019), https://www.tpr.org/post/bexar-county-approves-purchase-crime-lab-equipment-test-
marijuana-hemp. 
229 See Bogel-Burroughs, supra note 10.  
230 See generally UTAH ADMIN. CODE r. 68-26-3.3 (West 2020) (requiring third-party certification that an industrial 
hemp product’s composition is in compliance with state law). 
231 Small & Cronquist, supra note 96, at 408. 
232 Hemp Production and the 2018 Farm Bill: Hearing Before the Senate Comm. On Agriculture, Nutrition, & 
Forestry, 116th Congress 61 (2019) (statement of Erica Stark, Exec. Dir., Nat’l Hemp Ass’n). 
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raising the THC threshold may cause conflict with the federal statute, states are not federally 
preempted with respect to authorizing marijuana use.234  Therefore, an amendment to H.B. 1325, 
in which the Texas Legislature redefines hemp by raising the THC threshold, would both alleviate 
concerns regarding employees working while under the influence as well as preserve the right to 
access legal treatment for disabilities.  
 
As cannabis requires a concentration of at least one percent THC to produce a psychoactive 
effect,235 raising the permitted concentration from 0.3% to 0.5% would promote flexibility for law-
abiding consumers while also accommodating safety interests.236  Due to seasonal fluctuations and 
environmental influences, cannabis plants may contain “more or less THC than 0.3% at different 
times.”237  Additionally, the Texas Compassionate Use Act allows qualifying patients who suffer 
from specified illnesses to use cannabis containing 0.5% THC.238  While the Texas Legislature has 
explicitly stated that it will not decriminalize marijuana,239 it may be receptive to increasing the 
THC threshold by 0.2%, particularly after evaluating the benefits of doing so.  Raising the THC 
threshold for CBD would result in more flexibility for lawful users, and a continued absence of 
psychoactive effects.  However, while the increased threshold provides more flexibility, it does 
not in itself solve the issue of the State’s inability to test CBD. 
 
Between 2017 and 2018, fifty-two cases of CBD-related poisoning were reported in Utah.240  In 
2018, the Utah Department of Agriculture and Food responded by imposing administrative rules 
requiring registration of all hemp products.241  The rules require both manufacturers and 
distributors of CBD products to obtain a certificate of analysis of each CBD product from a third-
party lab.242  The product is then accompanied with a QR code or bar code that links to the 
certificate and appears similar to labels for dietary supplements.243  This policy ensures that label 
information is verified, and alleviates consumer concerns regarding CBD purity.244  The Utah 
 
234 See Barbuto v. Advantage Sales & Mktg., LLC, 78 N.E.3d 37, 45–46 (Mass. 2017). 
235 Small, supra note 15, at 252. 
236 See generally Steven B. Perlmutter, High Times Ahead: Products Liability in Medical Marijuana, 29 HEALTH 
MATRIX 225, 247-55 (2019).  As high levels of THC can cause adverse health effects such as anxiety or dizziness, a 
THC concentration well below the accepted minimum to induce psychoactive effects benefits public safety interests. 
237 Robert C. Clark, Interview, Dr. Ernest Small, 6 INT’L HEMP ASS’N (Dec. 1999), http://www.internationalhempas
sociation.org/jiha/jiha6208.html.  
238 TEX. OCC. CODE ANN. §§ 169.001(3), 169.003 (West 2019). 
239 See Letter from Greg Abbott, Governor of Tex., et al., to Tex. Dist. and Cty. Att’ys, supra note 106. 
240 Roberta Z. Horth et al., Notes from the Field: Acute Poisonings from a Synthetic Cannabinoid Sold as 
Cannabidiol – Utah, 2017-2018, CDC (May 25, 2018), 
https://www.cdc.gov/mmwr/volumes/67/wr/mm6720a5.htm?s_cid=mm6720a5_w#T1_down.  
241 Taylor Hartman, Utah Department of Agriculture and Food Announces New Rules for Sale of CBD Oils, FOX 13 
SALT LAKE CITY (Nov. 16, 2018), https://fox13now.com/2018/11/16/utah-department-of-agriculture-and-food-to-
register-hemp-based-products-like-cbd-oil-for-legal-purchase/.  
242 UTAH ADMIN. CODE r. 68-26-3.3 (West 2020). 
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Department of Agriculture and Food has begun working with retail stores to ensure that only 
compliant products are available for sale.245  
 
In Texas, the Department of State Health Services oversees CBD regulation.246  By adopting 
administrative rules modeled after those in Utah, the Department would transfer the burden of 
verifying CBD contents from the State to CBD manufacturers and distributors who seek 
participation in the Texas CBD market.  The possible bar on participation in the Texas CBD market 
would likely incentivize manufacturers, distributors, and private companies to establish labs in 
compliance with the administrative rules.  The U.S. Census Bureau estimates the Texas population 
as of July 2019 at nearly twenty-nine million people,247 making up almost nine percent of the total 
United States population.248  In 2019, Texas contributed over eight percent of the total United 
States gross domestic product.249  Therefore, CBD manufacturers and distributors face a 
substantial incentive to comply with any certificate analysis stipulations mandated by the 
Department of Health.   
 
The administrative rules should include a provision requiring Texas legislators to allocate funding 
for enforcement.  For example, Travis County legislators are currently debating whether to allocate 
funding for lab testing due to concerns that arrests for low-level marijuana possessions would 
“derail people’s lives.”250  In contrast, Bexar County recently allocated over $100,000 in city funds 
to obtain drug testing equipment.251  While such a provision would impose costs on the state, such 
costs would likely be mitigated by the burden-shifting mechanism of the verification rules.  In 
addition, it would likely motivate Texas legislators to allocate funding for lab testing, considering 
that CBD sales are projected to surpass twenty billion dollars  in the United States by 2024.252  
Thus, the adoption of administrative rules modeled after those in Utah, including a provision 
requiring funding for enforcement, would likely provide a solution to the current lack of available 
testing equipment. 
 
Finally, Chapter 21 of the Texas Labor Code should be amended to include a provision granting 
protection for employees who successfully prove that any alleged use of marijuana was actually 
 
245 Id. 
246 Sid Miller, Hemp Regulations, TEX. DEP’T AGRIC., https://www.texasagriculture.gov/RegulatoryPrograms/Hemp
.aspx (last visited Oct. 29, 2020). 
247 Quick Facts: Texas, U.S. CENSUS BUREAU, https://www.census.gov/quickfacts/TX (last visited Oct. 29, 2020). 
248 See National Population Totals and Components of Change: 2010-2019, U.S. CENSUS BUREAU, 
https://www.census.gov/data/tables/time-series/demo/popest/2010s-national-total.html#par_textimage_2011805803 
(last visited Oct. 29, 2020).  
249 Bureau of Econ. Analysis, Gross Domestic Product by State, Third Quarter 2019, U.S. DEP’T COM. tbl.3 (Jan. 
10, 2020), https://www.bea.gov/system/files/2020-01/qgdpstate0120_2.pdf.  
250 Joy Diaz, Austin Considers Not Buying Marijuana Testing Equipment, TEX. STANDARD (Jan. 13, 2020), 
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251 Poppe, supra note 228. 
252 Eamon Levesque, U.S. CBD Market Anticipated to Reach $20 Billion in Sales by 2024, BDS ANALYTICS (May 9, 
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use of CBD.  Unlike the ADA, Chapter 21 lacks a specific remedy for individuals who were 
wrongfully discriminated against on the basis of illegal drug use.253  A specific exception, modeled 
after that of the ADA,254 would provide individuals who lawfully used CBD with a procedure by 
which to appeal a decision or to combat an allegation of illegal drug use.  Therefore, if an individual 
uses CBD that has been verified in accordance with the proposed administrative rules but is found 





CBD use has rapidly risen over the past twenty years, specifically in the wake of the 2018 Farm 
Bill.255  At the same time, practical issues such as reliable drug testing equipment and FDA 
regulations have yet to be solved, resulting in confusion about what exactly consumers are 
ingesting when they purchase CBD products.  While CBD currently poses uncertainty at the 
federal level, it simultaneously does so at the state level. 
 
By passing H.B. 1325, the Texas Legislature took a step forward in the realm of cannabis 
decriminalization while repeatedly emphasizing its disinterest in decriminalizing marijuana,256 
forcing its citizens to choose between treating impairments with CBD and ensuring that they test 
negative for the presence of drugs.  
 
The government should amend H.B. 1325 to increase the THC threshold to 0.5%, implement rules 
requiring third-party verification of CBD purity, allocate state funding for enforcement, and amend 
the Labor Code to provide people wrongfully deemed as using illegal drugs with procedure to 
appeal such findings.  By implementing these policies, the Texas government may balance 
employers’ safety concerns with employees’ rights to access treatment without fear of 
discrimination.  
 
253 Compare 42 U.S.C.A. § 12114(b) (West 2009) (providing an exception for individuals who are incorrectly 
regarded as using drugs) with TEX. LAB. CODE. ANN. § 21.051 (West 2019). 
254 See 42 U.S.C.A. § 12114(b). 
255 See Mikulic, supra note 7. 
256 Jolie McCullough, Texas Leaders: Hemp Law Did Not Decriminalize Marijuana, TEX. TRIBUNE (July 18, 2019), 
https://www.texastribune.org/2019/07/18/greg-abbott-texas-leaders-hemp-marijuana-law/. 
